Subclinical hypothyroidism increases insulin resistance in normoglycemic people.
diabetes
insulin resistance
subclinical hypothyroidism
thyroid hormone sensitivity
thyroid stimulating hormone
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
24
11
2022
accepted:
22
06
2023
medline:
26
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
To investigate the effect of simple subclinical hypothyroidism (SCH) and type 2 diabetes mellitus (T2DM) combined with SCH on insulin resistance. A total of 622 people with newly diagnosed T2DM were selected as the study subjects, and 621 normoglycemic people were selected as control subjects. According to the diagnostic criteria of thyroid diseases, the subjects were divided into a normal thyroid function group and a subclinical hypothyroidism group. Both groups received a physical examination, and blood samples were collected. The measurement indexes included FPG, FINS, OGTT2hPG, OGTT2hINS, HbA1c, TC, TG, HDL-C, LDL-C, TSH, FT3 and FT4. HOMA-IR, HOMA-β, and TFQI (thyroid feedback quantile index) were calculated. There was no significant difference in age or sex distribution between the T2DM group and the normoglycemic group (P>0.05). The prevalence of thyroid dysfunction in the T2DM group was significantly higher than that in the normoglycemic group (16.39% vs. 11.27%, P<0.05), and among the different types of thyroid dysfunction, the prevalence of SCH was the highest at 14.95% (P<0.05). There was no significant difference in BMI, waist-hip ratio, blood lipid profile, HOMA-β, and HOMA-IR values between the T2DM with subclinical hypothyroidism group (T2DM+SCH+ group) and the normal thyroid function group (T2DM+SCH- group) (P>0.05). The BMI, waist-hip ratio and HOMA-IR values of the normoglycemic group with subclinical hypothyroidism (T2DM-SCH+ group) were significantly higher than those of the normoglycemic group with normal thyroid function (T2DM-SCH- group) (P<0.05), and there were no significant differences between the T2DM+SCH- and T2DM+SCH+ groups (P>0.05). HOMA-β values were significantly higher in the T2DM-SCH+ group than in the T2DM-SCH-, T2DM+SCH- and T2DM+SCH+ groups (P<0.05). As the TFQI value increased, the body weight, waist-hip ratio, diastolic blood pressure, FPG, OGTT2hPG and HbA1c values gradually increased in the T2DM group and normoglycemic group (P<0.05). HDL-C, FINS, OGTT2hINS and HOMA-β values gradually decreased (P<0.05). Subclinical hypothyroidism only increases insulin resistance in normoglycemic people. As the sensitivity of the central thyroid decreases, the risk of developing diabetes increases.
Identifiants
pubmed: 37484968
doi: 10.3389/fendo.2023.1106968
pmc: PMC10358968
doi:
Substances chimiques
Glycated Hemoglobin
0
Thyrotropin
9002-71-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1106968Informations de copyright
Copyright © 2023 Yang, Jin, Wang, Lai, Li and Shan.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer XS declared a shared affiliation with the authors to the handling editor at the time of review.
Références
J Cell Biochem. 2018 Jul;119(7):5016-5027
pubmed: 29236298
Mymensingh Med J. 2017 Oct;26(4):874-878
pubmed: 29208878
Exp Ther Med. 2021 Sep;22(3):1033
pubmed: 34373719
Br J Cancer. 1995 Jul;72(1):1-9
pubmed: 7599035
Curr Opin Rheumatol. 2013 Mar;25(2):210-6
pubmed: 23370374
Mol Cell Endocrinol. 2021 Feb 5;521:111097
pubmed: 33278491
Eur J Endocrinol. 2009 May;160(5):785-90
pubmed: 19141606
Endocr Rev. 2019 Jun 1;40(3):789-824
pubmed: 30649221
J Endocrinol. 2002 Jul;174(1):121-5
pubmed: 12098670
J Diabetes Investig. 2022 Nov;13(11):1889-1896
pubmed: 35778970
Diabetes Metab Syndr. 2019 Jan - Feb;13(1):468-473
pubmed: 30641746
Int J Environ Res Public Health. 2021 Sep 07;18(18):
pubmed: 34574358
BMC Med. 2021 Oct 21;19(1):257
pubmed: 34670571
Diabetes Care. 2019 Feb;42(2):303-310
pubmed: 30552134
Endocr Res. 2013;38(1):15-23
pubmed: 22746188
Thyroid. 2016 Oct;26(10):1441-1449
pubmed: 27599541
Nutr Metab Cardiovasc Dis. 2018 Feb;28(2):173-179
pubmed: 29239740
Med Arh. 2007;61(1):20-1
pubmed: 17582969
Thyroid. 2013 Jun;23(6):646-53
pubmed: 22934923
Thyroid. 2017 Jan;27(1):29-38
pubmed: 27809684
Diabetes Metab Syndr. 2019 Jul - Aug;13(4):2513-2517
pubmed: 31405670
BMJ. 2020 Apr 28;369:m997
pubmed: 32345662
Front Public Health. 2021 Jul 23;9:678681
pubmed: 34368053
Acta Pharmacol Sin. 2018 Jul;39(7):1176-1188
pubmed: 29877321
Diabetes Metab Syndr. 2018 Nov;12(6):863-867
pubmed: 29748035
Ther Adv Endocrinol Metab. 2020 May 13;11:2042018820917869
pubmed: 32489580
Diabetol Metab Syndr. 2013 Oct 09;5(1):58
pubmed: 24499529
Front Endocrinol (Lausanne). 2017 Nov 14;8:314
pubmed: 29184536
Diabet Med. 2002 Jan;19(1):70-3
pubmed: 11869306
J Coll Physicians Surg Pak. 2017 Jun;27(6):329-333
pubmed: 28689519
J Diabetes. 2021 Apr;13(4):318-329
pubmed: 32981234
Diabetol Metab Syndr. 2014 Sep 16;6(1):99
pubmed: 25276234
Endocrine. 2013 Dec;44(3):716-22
pubmed: 23468096
Physiol Rev. 2014 Apr;94(2):355-82
pubmed: 24692351
Int J Endocrinol. 2015;2015:570198
pubmed: 26435714
Diabetes Metab Syndr. 2020 Nov-Dec;14(6):2147-2151
pubmed: 33395774